Glycine-extended gastrin exerts growth-promoting effects on human colon cancer cells

Mol Med. 1999 Mar;5(3):147-59.

Abstract

Background: Since human colon cancers often contain significant quantities of progastrin-processing intermediates, we sought to explore the possibility that the biosynthetic precursor of fully processed amidated gastrin, glycine-extended gastrin, may exert trophic effects on human colonic cancer cells.

Materials and methods: Binding of radiolabeled glycine-extended and amidated gastrins was assessed on five human cancer cell lines: LoVo, HT 29, HCT 116, Colo 320DM, and T 84. Trophic actions of the peptides were assessed by increases in [3H]thymidine incorporation and cell number. Gastrin expression was determined by northern blot and radioimmunoassay.

Results: Amidated gastrin did not bind to or stimulate the growth of any of the five cell lines. In contrast, saturable binding of radiolabeled glycine-extended gastrin was seen on LoVo and HT 29 cells that was not inhibited by amidated gastrin (10(-6) M) nor by a gastrin/CCKB receptor antagonist (PD 134308). Glycine-extended gastrin induced a dose-dependent increase in [3H]thymidine uptake in LoVo (143 +/- 8% versus control at 10(-10) M) and HT 29 (151 +/- 11% versus control at 10(-10) M) cells that was not inhibited by PD 134308 or by a mitogen-activated protein (MAP) or ERK kinase (MEK) inhibitor (PD 98509). Glycine-extended gastrin did stimulate jun-kinase activity in LoVo and HT 29 cells. The two cell lines expressed the gastrin gene at low levels and secreted small amounts of amidated gastrin and glycine-extended gastrin into the media.

Conclusions: Glycine-extended gastrin receptors are present on human colon cancer cells that mediate glycine-extended gastrin's trophic effects via a MEK-independent mechanism. This suggests that glycine-extended gastrin and its novel receptors may play a role in colon cancer cell growth.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Binding Sites
  • Binding, Competitive
  • Calcium-Calmodulin-Dependent Protein Kinases / drug effects
  • Calcium-Calmodulin-Dependent Protein Kinases / metabolism
  • Cell Division / drug effects
  • Colonic Neoplasms / drug therapy
  • Colonic Neoplasms / metabolism*
  • Colonic Neoplasms / pathology*
  • DNA-Binding Proteins*
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Flavonoids / pharmacology
  • Gastrins / genetics
  • Gastrins / metabolism*
  • Gastrins / pharmacology*
  • Gene Expression Regulation / drug effects
  • Humans
  • Indoles / pharmacology
  • JNK Mitogen-Activated Protein Kinases
  • Meglumine / analogs & derivatives
  • Meglumine / pharmacology
  • Mitogen-Activated Protein Kinases*
  • Peptide Fragments / metabolism*
  • Peptide Fragments / pharmacology*
  • Protein Processing, Post-Translational
  • Proto-Oncogene Proteins / drug effects
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / metabolism
  • Rats
  • Receptors, Cholecystokinin / drug effects
  • Receptors, Cholecystokinin / metabolism*
  • Recombinant Proteins / drug effects
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism
  • Response Elements
  • Signal Transduction
  • Tetradecanoylphorbol Acetate / pharmacology
  • Transcription Factors*
  • Tumor Cells, Cultured
  • ets-Domain Protein Elk-1

Substances

  • Antineoplastic Agents
  • DNA-Binding Proteins
  • Elk1 protein, rat
  • Enzyme Inhibitors
  • Flavonoids
  • Gastrins
  • Indoles
  • Peptide Fragments
  • Proto-Oncogene Proteins
  • Receptors, Cholecystokinin
  • Recombinant Proteins
  • Transcription Factors
  • ets-Domain Protein Elk-1
  • gastrin (2-17)-Gly, Leu(15)-
  • PD 134308
  • Meglumine
  • Calcium-Calmodulin-Dependent Protein Kinases
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinases
  • Tetradecanoylphorbol Acetate
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one